Chicago-based Xeris Biopharma has hauled two generic rivals into federal court, filing suit on Tuesday to stop would-be copycats of Recorlev, its treatment for endogenous Cushing’s syndrome. The complaint, lodged in the U.S. District Court for the District of New Jersey, targets Torrent Pharmaceuticals and Somerset Therapeutics and asks the court to block manufacture, use or sale of the companies’ levoketoconazole products while Xeris’ patents are still in force. Patients, prescribers and investors will be watching closely to see how quickly a lower‑cost alternative might, or might not, reach the U.S. market.
What Xeris Is Telling The Judge
Xeris says its subsidiaries, Xeris Pharmaceuticals and Strongbridge Dublin, brought the case after receiving Paragraph IV certification notices from the two Abbreviated New Drug Application filers. According to Xeris, the generics are challenging four Orange Book‑listed patents that run through March 2040. In a Form 8‑K filed with the SEC and posted on StockTitan, the company identifies the patents as U.S. Patent Nos. 11,020,393; 11,278,547; 11,903,940; and 12,377,096 and says the complaint asks for an injunction stopping the manufacture or sale of the proposed generics while those patents remain in effect. “We are confident in the quality and strength of the intellectual property we have developed for Recorlev,” CEO John P. Shannon said in the company filing.
How Hatch‑Waxman Can Slow The Generics Down
Under the Hatch‑Waxman framework, when a generic maker files an Abbreviated New Drug Application with a Paragraph IV certification, the brand‑name company gets a short window to sue. If it does sue in time, FDA approval of the generic is typically put on hold for up to 30 months while the patent fight plays out. As a Congressional Research Service primer explains, that automatic “30‑month stay” is meant to give patent owners breathing room to argue their case in court, although a decision finding a patent invalid or not infringed can cut the delay short. That statutory lever is the key tool Xeris is now pulling to keep generic levoketoconazole off the market while it defends its patents.
Why Recorlev Looms So Large
Recorlev won FDA approval in December 2021 and carries orphan‑drug exclusivity through December 2028, protections that help shore up Xeris’ market position. According to Biospace, Recorlev net revenue more than doubled year‑over‑year in 2024, making the drug a major commercial driver for the company. For patients who depend on the therapy, whether a generic makes it to pharmacy shelves could translate into meaningful differences in price and access.
What To Watch Next In New Jersey
The case now sits before the federal court in New Jersey, and Xeris has warned in its filing that more Paragraph IV notices from additional ANDA filers could still land. Investors are already reacting: market reports said Xeris shares dipped after the lawsuit was disclosed. From here, expect early scheduling orders, skirmishes over the strength and scope of the patents, and behind‑the‑scenes settlement talks that could ultimately determine when, or if, a lower‑cost Recorlev generic reaches patients.
